RxDoctor Payments Data

Sejan Patel, MD

Nephrology · Cary, NCNPI 1417149717

Payments from drug & device makers

$3,906in general payments, 2019–2025

Across 142 payments — averaging $27.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$2K
  • Amgen$456
  • Otsuka America Pharmaceutical, Inc.$436
  • W. L. Gore & Associates, Inc.$358
  • Fresenius USA Marketing, Inc.$293
  • AstraZeneca$108
  • plus $580 from 17 others

What the payments were for

  • Travel & lodging$1,05427%
  • Food & beverage$2,82372%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,906 in reported general payments places this provider in the 65th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$183,471
Medicare patients
422
Services billed
1,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide25$98,500
FarxigaDapagliflozin Propanediol86$48,806
Sevelamer Carbonate38$5,144
Bumetanide31$1,147
Midodrine Hcl18$967
Gentamicin Sulfate21$549
Amlodipine Besylate62$403
Lisinopril33$400
Tamsulosin Hcl18$384
Hydralazine Hcl22$354
Losartan Potassium43$272
Clonidine Hcl12$205
Carvedilol12$190
Furosemide49$127
Potassium Chloride12$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$293$98,50025 claims
AstraZenecaFarxiga$108$48,80686 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →